Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Breast cancer, female
Stage/Subtype:  triple-negative breast cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 63 for your search:
Start Over
Olaparib in Treating Patients with Triple-Negative Non-metastatic Breast Cancer Who Have Completed Definitive Local Treatment and Chemotherapy
Phase: Phase III
Type: Natural history/Epidemiology, Treatment
Age: 18 and over
Trial IDs: NSABP-B-55, NCI-2014-00644, BIG 6-13, D081CC00006, NCT02032823
Platinum Based Chemotherapy or Observation in Treating Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EA1131, NCI-2014-01820, NCT02445391
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel with or without Carboplatin in Treating Patients with Triple-Negative Breast Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NRG-BR003, NCI-2015-00128, NRG-BR1428, NCT02488967
Cediranib Maleate and Olaparib in Treating Patients with Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 09-293, NCI-2012-02938, DFCI IRB 09-293, NCI-2010-01329, NCI-2013-00578, NCT01115829, 8348, NCT01116648
Multitargeted Tyrosine Kinase Inhibitor PLX3397 and Eribulin Mesylate in Treating Patients with Triple-Negative Breast Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12751, NCI-2015-01321, 141658, CC#12751, NCT01596751
A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA209-032, NCI-2013-02337, 2013-002844-10, NCT01928394
Ruxolitinib Phosphate and Chemotherapy before Surgery in Treating Patients with Recurrent, Metastatic, or Triple-Negative Inflammatory Breast Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 13-494, NCI-2015-00620, I-Rux-12-06, NCT02041429
Olaparib and mTOR Kinase Inhibitor AZD2014 or AKT Inhibitor AZD5363 in Treating Patients with Recurrent Endometrial, Triple Negative Breast, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2013-0784, NCI-2014-01973, NCT02208375
A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PCYC-1135-CA, NCI-2015-00591, NCT02403271
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed By Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: 6628, NCI-2010-00041, FHCRC-6628, UWCC-6628, UWHSD# 33866, GENENTECH-FHCRC-6628, NCT00733408
Laboratory Treated T Cells after Chemotherapy in Treating Patients with HER2-Negative Stage II-III Breast Cancer That Can Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2010-056, NCI-2011-02634, 1005008403, CDR0000675211, NCT01658969, WSU-2010-056, NCT01147016
Ruxolitinib Phosphate in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-024, NCI-2012-00992, NCT01562873
Paclitaxel and Cyclophosphamide with or without Trastuzumab before Surgery in Treating Patients with Previously Untreated Stage I-III Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 264-12, NCI-2012-01372, NCT01750073
Carboplatin and Combination Chemotherapy with or without Veliparib in Treating Patients with Stage IIA-IIIC Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12G.376, NCI-2013-00594, 2012001, 2012-47, 2997, NCT01818063
Eribulin Mesylate in Treating Patients with HER2-Negative Metastatic Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-077, NCI-2013-01115, NCT01827787
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients with Metastatic Triple-Negative Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU 13117, NCI-2013-01895, 2013C0069, NCI 9455, 9455, NCT01964924
Cisplatin or Paclitaxel before Surgery in Treating Patients with Triple Negative Stage I-III Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-383, NCI-2014-00955, 030, TBCRC 030, NCT01982448
Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CDX011-04, NCI-2014-00373, NCT01997333
Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: BRE12-158, NCI-2015-00307, NCT02101385
Neoadjuvant Treatment of Triple Negative Breast Cancer Patients with Docetaxel and Carboplatin to Assess Anti-tumor Activity
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 201404107, NCI-2014-01037, NCT02124902
A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Front-line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: GO29227, NCI-2014-01665, 2014-000469-35, NCT02162719
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With FGF Aberrant Metastatic Breast Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CO-3810-025, NCI-2014-01992, NCT02202746
Start Over